193274-02-1

Basic information

• Product Name: 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-, 1,1-dimethylethyl ester
• CAS NO: 193274-02-1
• Molecular Formula: C19H25N3O3
• Molecular Weight: 343.426
• Mol File: 193274-02-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-, 1,1-dimethylethyl ester(193274-02-1)
• EPA Substance Registry System: 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-, 1,1-dimethylethyl ester(193274-02-1)

Safety Data

• Hazardous Substances Data: 193274-02-1(Hazardous Substances Data)

Usage

General Description

5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-, 1,1-dimethylethyl ester is a chemical compound with a complex structure. 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-, 1,1-dimethylethyl ester is a derivative of pyrazole and pyridine, two aromatic heterocyclic compounds. It contains a carboxylic acid group, a hexahydro-2-methyl-3-oxo-3a-(phenylmethyl) group, and a 1,1-dimethylethyl ester. 5H-Pyrazolo[4,3-c]pyridine-5-carboxylic acid, 2,3,3a,4,6,7-hexahydro-2-methyl-3-oxo-3a-(phenylmethyl)-, 1,1-dimethylethyl ester may have applications in pharmaceuticals or organic synthesis, given its unique structure and functional groups. Further research and analysis may be needed to fully understand the properties and potential uses of this compound.

Upstream product

• 193274-00-9 3-(R,S)-benzyl-4-oxo-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 60-34-4 methylhydrazine 
• 193274-00-9 3-(R,S)-Benzyl-4-oxo-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 
• 161491-24-3 methyl 1-tert-butoxycarbonyl-4-oxo-3-piperidinecarboxylate 
• 108554-34-3 methyl 4-oxonipecotate 

Downstream Products

• 193274-09-8 {1-[2-(3a-(S)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethylcarbamoyl]-1-methyl-ethyl}carbamic acid tert-butyl ester 
• 193274-08-7 {1-[2-(3a-(R)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo[4,3-c]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethylcarbamoyl]-1-methyl-ethyl}carbamic acid tert-butyl ester 
• 193274-37-2 (R)-3a-benzyl-2-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridin-3(3aH)-one (2R,3R)-2,3-dihydroxysuccinate 
• 193273-66-4 capromorelin 
• 193273-66-4 2-amino-N-[2-(3a-(S)-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-[4,3-c ]pyridin-5-yl)-1-(R)-benzyloxymethyl-2-oxo-ethyl]-isobutyramide 
• 193274-04-3 3a-(R)-Benzyl-2-methyl-2,3a,4,5,6,7-hexahydro-pyrazolo[4,3-c]pyridin-3-one 

Relevant articles and documents

Combinations of β3 agonists and growth hormone secretagogues

This invention is directed to pharmaceutical compositions comprising β3adrenergic agonists including (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)acetic acid and growth hormone or growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to methods of using those compositions in the treatment of obesity, diabetes, hypertension and frailty in animals and particularly in humans.

Treatment of insulin resistance with growth hormone secretagogues

This invention is directed to methods of treating insulin resistance in a mammal which comprise administering an effective amount of a compound of formula I, where the variables are defined in the specification, or the stereoisomeric mixtures, diastereomerically enriched, diastereomerically pure, enantiomerically enriched or enantiomerically pure isomers, or the pharmaceutically acceptable salts and prodrugs thereof to said mammal. The compounds of formula I are growth hormone secretagogues and as such are useful for increasing the level of endogenous growth hormone. In another aspect this invention provides certain intermediates which are useful in the synthesis of the foregoing compounds and certain processes useful for the synthesis of said intermediates and the compounds of formula I. This invention is further directed to methods comprising administering to a human or other animal a combination of a functional somatostatin antagonist such as an alpha-2 adrenergic agonist and a compound of formula I.

Process for preparing growth hormone secretagogues

This invention relates to improved processes for preparing compounds of Formula II, and compounds of Formula III, wherein R1, R2, R3 and Prt are defined as set forth in the specification.